Transgenic Expression of Cyclooxygenase-2 in Hepatocytes Accelerates Endotoxin-Induced Acute Liver Failure

Chandrashekhar R. Gandhi and Tong Wu

*J Immunol* 2008; 181:8027-8035; doi: 10.4049/jimmunol.181.11.8027

http://www.jimmunol.org/content/181/11/8027

**References** This article cites 51 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/181/11/8027.full#ref-list-1

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions** Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Transgenic Expression of Cyclooxygenase-2 in Hepatocytes Accelerates Endotoxin-Induced Acute Liver Failure

Chang Han,2* Guiying Li,† Kyu Lim,‡ Marie C. DeFrances,agr Chandrashekhar R. Gandhi,agr and Tong Wu2‡

Bacterial LPS (endotoxin) is implicated in the pathogenesis of acute liver failure and several chronic inflammatory liver diseases. To evaluate the effect of hepatocyte cyclooxygenase (COX)-2 in LPS-induced liver injury, we generated transgenic mice with targeted expression of COX-2 in the liver by using the albumin promoter-enhancer driven vector and the animals produced were subjected to a standard experimental protocol of LPS-induced acute fulminant hepatic failure (i.p. injection of low dose of LPS in combination with d-galactosamine (d-GalN)). The COX-2 transgenic mice exhibited earlier mortality, higher serum aspartate aminotransferase and alanine aminotransferase levels and more prominent liver tissue damage (parenchymal hemorrhage, neutrophilic inflammation, hepatocyte apoptosis, and necrosis) than wild-type mice. Western blot analysis of the liver tissues showed that LPS/d-GalN treatment for 4 h induced much higher cleavage of poly(ADP-ribose) polymerase, caspase-3, and caspase-9 in COX-2 transgenic mice than in wild-type mice. Increased hepatic expression of JNK-2 in COX-2 transgenic mice suggest that up-regulation of JNK-2 may represent a potential mechanism for COX-2-mediated exacerbation of liver injury. Blocking the prostaglandin receptor, EP1, prevented LPS/d-GalN-induced liver injury and hepatocyte apoptosis in COX-2 transgenic mice. Accordingly, the mice with genetic ablation of EP1 showed less LPS/d-GalN-induced liver damage and less hepatocyte apoptosis with prolonged survival when compared with the wild-type mice. These findings demonstrate that COX-2 and its downstream prostaglandin receptor EP1 signaling pathway accelerates LPS-induced liver injury. Therefore, blocking COX-2-EP1 pathway may represent a potential approach for amelioration of LPS-induced liver injury.


D espite the current progress in clinical medicine, sepsis continues to pose major clinical problems and is associated with high patient mortality (1). Bacterial LPS (endotoxin) is the major component of the outer membrane from the Gram-negative bacteria and is critically involved in the development of sepsis. LPS induces fever, hypotension, intravascular coagulation, and finally failure of vital organs, including acute liver failure, which is often refractory to clinical treatment (2, 3). LPS has been shown to induce the expression of cyclooxygenase (COX)-2 in a variety of human cells including hepatic cells (4, 5); however, the biological role of COX-2 in LPS-induced tissue injury remains unknown.

COX-2 plays a key role in the pathogenesis of inflammation, for its expression is markedly up-regulated by inflammatory stimuli leading to increased synthesis of prostanoids (potent lipid inflammatory mediators) in inflamed tissues. PGE2 is the most abundant prostabond detected in inflamed tissues and its effect is mediated through activation of the EP receptor subtypes located in the plasma membrane (EP1, EP2, EP3, and EP4), which belong to the G protein-coupled receptor superfamily of seven-transmembrane spanning proteins (6–8). In fact, the conventional view that LPS-induced fever is mediated by pyrogenic cytokines is being gradually replaced by the concept that it is initiated by the production of PGE2 (9, 10).

In addition to the role of LPS in acute liver injury, LPS derived from intestinal bacteria is also implicated in the pathogenesis of chronic inflammatory liver diseases, such as chronic hepatitis, alcoholic liver disease and cirrhosis (11, 12). Given that Gram-negative bacteria normally colonize the colon, the body has developed strong defensive mechanisms that tightly regulate the entry and processing of LPS (13). The liver plays a central role in this process by virtue of its dual ability not only to clear LPS, but to actively respond to LPS. Consequently, several molecular mechanisms of inflammation and cellular damage have been implicated in the pathogenesis of LPS hepatotoxicity, including those related to the overt generation of inflammatory cytokines and oxygen free radicals from Kupffer cells; however, the potential role of liver parenchymal cells in LPS-induced liver injury has not been defined.

In the present study, we hypothesized that COX-2 activation in hepatocytes might accelerate LPS-induced liver injury and, therefore, interruption of the COX-2 cascade could attenuate LPS-induced tissue damage. This hypothesis was tested by both genetic and pharmacological approaches. We generated a novel transgenic mouse model with targeted expression of COX-2 in the liver and showed that hepatic expression of COX-2 sensitized the liver to LPS-induced tissue damage and liver failure. Furthermore, we showed that the LPS/d-GalN-induced liver damage in the COX-2 transgenic mice is attenuated by pretreatment with NS-398, a selective

Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/52.00

www.jimmunol.org
COX-2 inhibitor, or ONO-8711, a specific antagonist for the prostaglandin receptor subtype EP₁. Accordingly, the mice with genetic ablation of EP₁ showed less LPS/D-GalN-induced liver damage and less hepatocyte apoptosis with prolonged survival when compared with the wild-type mice. These results demonstrate an important role of COX-2/EP₁ signaling cascade in LPS-induced hepatic injury and suggest that blocking this pathway may represent a novel target for amelioration of LPS-induced liver injury.

Materials and Methods

Animals

Transgenic mice with targeted expression of COX-2 in the liver were developed by using the well-established albumin promoter-enhancer driven vector. To construct the albumin promoter-COX-2 transgene, a 1.8-kb human COX-2 cDNA containing the entire coding region of human COX-2 was inserted into the first exon of the human growth hormone gene controlled by the mouse albumin enhancer/promoter (14, 15). This transgene was microinjected into mouse zygotes (B6SJL/F1, eggs) at the transgenic core facility of the University of Pennsylvania according to our contract. Five transgenic lines were produced and the mice were brought back to the University of Pittsburgh animal facility for propagation. The transgenic lines were maintained by backcrossing to the C57BL/6 wild-type mice. The transgenic mice were identified by genotyping using tail DNA samples. The COX-2 transgenic mice used in this study were derived from one transgenic line that was backcrossed to C57BL/6 wild-type mice for five consecutive generations. The mice at the age of 8–12 wk were used for experiments, with age- and sex-matched wild-type C57BL/6 mice as controls. The animals were kept at 22°C under a 12-h light/dark cycle and received food and water ad libitum.

Protocol

The COX-2 transgenic mice and the age- and sex-matched wild-type mice were administered i.p. 30 μg/g body weight of LPS (Escherichia coli O55: B6; Sigma-Aldrich) in combination with 800 μg/g body weight of d-galactosamine (D-GalN) (Sigma-Aldrich) to induce acute fulminant hepatic failure (the reagents were dissolved in sterile nonpyrogenic saline solution). All experimental animals used in this study were treated according to the protocol approved by the University of Pittsburgh Animal Care and Use Committee (Protocol No. 0303501).

Assessment of hepatotoxicity and survival rate

To determine the survival rate, the animals were monitored continuously after LPS/D-GalN injection until animal death. In other experiments, the animals were sacrificed at specific time points to obtain blood and liver tissues. The blood samples were centrifuged at 3000 rpm for 15 min, and the serum was collected and stored at –80°C. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were measured using an automatic analyzer at the University of Pittsburgh Medical Center Chemistry Department. The liver tissues were subjected to standard formalin fixation and paraffin embedding for histological evaluation and TUNEL stain.

H&E staining

For histological analysis, liver tissue was fixed in 10% neutral-buffered formalin and embedded in paraffin. Sections of 5-μm thickness were affixed to slides, deparaffinized, and stained with H&E to determine morphologic changes.

TUNEL stain

The extent of hepatocyte apoptosis was detected by TUNEL. TUNEL-positive cells were counted by randomly selecting high-power fields (×400) distributed over 3–5 independent sections. The number of TUNEL-positive and TUNEL-negative cells was compiled, and the percentage of TUNEL-positive cells was calculated.

Immunohistochemical stain for caspase-3

Formalin-fixed, paraffin-embedded sections of the liver tissues were subjected to immunohistochemical analysis for caspase-3. The 5-μm thick tissue sections were deparaffinized and rehydrated, followed by microwave retrieval of Ag according to standard procedures. The slides were sequentially blocked with avidin and biotin and then incubated at 4°C overnight with 1/100 diluted anti-human COX-2 Ab.

FIGURE 1. Generation of COX-2 transgenic mice. The COX-2 transgene (complete human COX-2 cDNA cloned into the albumin promoter-driven vector) was microinjected into mouse zygotes to generate transgenic mice by established method. A, Schematic representation of the human COX-2 transgene with albumin promoter using the human growth hormone (h-GH) gene. B, Southern blot analysis of tail genomic DNA showing the presence of COX-2 transgene in transgenic (TG) but not in wild-type (WT) littersmates. The DNA samples were digested with Bam H1; the blot was hybridized with [32P]-labeled human COX-2 cDNA probe. C, PCR analysis of tail genomic DNA showing the presence of COX-2 transgene in transgenic (TG) mice but not in wild-type (WT) littersmates. D, Western blot showing successful expression of COX-2 protein in the liver tissues from COX-2 transgenic mice. Equal amounts of the mouse liver tissue proteins from transgenic mice (TG) and wild-type (WT) littersmates were subjected to SDS-PAGE and Western blotting using anti-human COX-2 Ab.

FIGURE 2. PGE₂ levels in the liver tissues from wild-type and COX-2 transgenic (Tg) mice. Liver tissues were homogenized and extracted in 100 mg Amrep C18 Minicolumn. The eluted samples were dried and the amounts of PGE₂ were determined by specific enzyme immuno assay. Data are presented as mean ± SD in picograms per milligram of liver tissue. *, p < 0.01 compared with wild-type mice (n = 6).
received a single i.p. injection of LPS/D-GalN. The animals were closely monitored
and sex-matched wild-type mice were administered i.p. 30 ng/g body weight of LPS in combination with 800 g/g body weight of D-GalN. The animals
were sacrificed 4 h after injection. Blood samples were collected and sera were separated for transaminase analysis. The COX-2 transgenic mice show
significantly higher serum ALT and AST levels than the wild-type mice after LPS/D-GalN treatment (data not shown).

Table I. Survival rate of wild-type, COX-2 transgenic, and EP1
knockout mice after LPS/D-GalN injection

<table>
<thead>
<tr>
<th>Postinjection, h</th>
<th>Wild Type</th>
<th>COX-2 Transgenic</th>
<th>EP1 Knockout</th>
<th>Saline Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>16</td>
<td>16</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>10</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>14</td>
<td>6</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>4</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>0</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>12</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>24</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

The COX-2 transgenic, EP1 knockout and wild-type mice at 6–8 wk of age received a single i.p. injection of LPS/D-GalN. The animals were closely monitored for activity, and mortality was documented at hourly intervals (up to 24 h).

Rabbit anti-caspase-3 (catalog no. 9661; Cell Signaling Technology). Following
repeated washings, the slides were incubated at room temperature for 30 min with biotinylated goat anti-rabbit (catalog no. BA-1000, 1:200 dilution
with 3X goat serum; Vector Laboratories). The slides were then washed and
incubated with ABC/HRP at room temperature for 30 min (PK-6100; Vector
Laboratories) according to the manufacturer’s instruction. The 3-amino-9-ethylcarbazole substrate/chromogen was used for color development followed by
counter-staining with hematoxylin.

Analysis of cytokine production

To analyze cytokine levels in the liver, mice were sacrificed 4 h after
LPS/D-GalN injection and the liver was removed immediately. The liver
tissue was homogenized in PBS containing protease inhibitors. The ob-
tained supernatants were stored at –80°C and analyzed for cytokine levels
at the University of Pittsburgh Luminex Core Facility by the Luminex
counter-staining with hematoxylin. Mouse cytokine bead immunoassay kit (BioSource International) according to the manufacturer’s instructions.

Measurement of PGE2 level

The liver tissues from wild-type and COX-2 transgenic mice were homog-
enized and then extracted in 100 mg of Amprep C18 Minicolumn. The
eluted samples were dried, and the amounts of PGE2 were determined by
specific enzyme immune assay as we previously described (16).

Immunoblotting

Mouse liver tissues were homogenized with cold PBS containing 0.5 mM
PMSF and 10 μg/ml leupeptin and resuspended in 5-fold volume of hy-
portonic buffer consisting of 50 mM HEPES (pH 7.55), 1 mM EDTA, 1 mM
DTT, and protease inhibitor cocktail tablets (Roche Diagnostics). The cell
lysate was collected by centrifugation at the speed of 15,000 × g at 4°C for
10 min to remove cell debris and stored in aliquots at –20°C until use. The
protein concentrations in the cell extracts were determined by the Bio-Rad
protein assay. The 30 μg of cellular protein was subjected to SDS-PAGE,
and the separated proteins were electrophoretically transferred onto the
nitrocellulose membranes (Bio-Rad). Nonspecific binding was blocked with PBS-T (0.5% Tween 20 in PBS) containing 5% nonfat milk for 1 h at
room temperature. The membranes were then incubated overnight at 4°C
with Abs against JNK-2, phospho-JNK, caspase-3, caspase-9, and poly-
(ADP-ribose) polymerase (PARP) in PBS-T containing 1% nonfat milk at the
dilutions specified by the manufacturers. Following three washes with
PBS-T, the membranes were then incubated with the HRP-conjugated sec-
cordary Abs at 1/10,000 dilution in PBS-T containing 1% nonfat milk for
1 h at room temperature. The membranes were then washed three times with
PBS-T and the protein bands were visualized with the ECL Western
blotting detection system according to the manufacturer’s instructions.

β-actin was used as the loading control.

Results

To determine the effect of hepatocyte COX-2 in LPS-induced liver injury, we developed transgenic mice with targeted expression of
COX-2 in the liver by using the well-established albumin promoter-enhancer driven vector (Fig. 1). These mice were generated by
microinjection of the COX-2 transgene (complete COX-2 cDNA cloned into the albumin promoter-driven vector (14, 15)) into
mouse zygotes. The function of expressed COX-2 is supported by
elevated production of PGE2 in the liver tissue homogenates of
COX-2 transgenic mice (57.17 ± 7.72 pg/mg liver tissue in
COX-2 transgenic mice vs 24.26 ± 5.24 pg/mg liver tissue in
wild-type mice; p < 0.01, n = 6) (Fig. 2). These COX-2 transgenic
mice develop normally with no significant liver inflammation or histologic abnormality under normal housing conditions. How-
ever, the COX-2 transgenic mice exhibited early mortality than
wild-type mice when the animals were subjected to a standard experimental protocol of LPS-induced acute fulminant hepatic
failure (i.p. injection of low dose of LPS in combination with D-
GalN) (17–23). In COX-2 transgenic group (n = 16 mice), mor-
tality became apparent at 5–6 h and all mice died by 9 h (Table I).

![FIGURE 3](http://www.jimmunol.org/)

**FIGURE 3.** Hepatic expression of COX-2 enhances serum transaminase levels induced by LPS. The COX-2 transgenic (COX-2 tg) mice and the age- and sex-matched wild-type mice were administered i.p. 30 mg/g body weight of LPS in combination with 800 μg/g body weight of n-GalN. The animals were sacrificed 4 h after injection. Blood samples were collected and sera were separated for transaminase analysis. The COX-2 transgenic mice show significantly higher serum ALT and AST levels than the wild-type mice after LPS/n-GalN treatment (p < 0.01 compared with wild-type mice treated with LPS/n-GalN). Similar transaminase levels were observed between COX-2 transgenic and wild-type mice when the animals were not subjected to LPS/n-GalN treatment (data not shown).
In wild-type mice \((n = 16)\), no death was observed at 6 h; first animal death was observed at 7 h and all animals died by 11 h.

Based on the survival rate, additional COX-2 transgenic and wild-type mice were sacrificed 4 h after LPS/\(\alpha\)-GalN administration to obtain blood samples and liver tissues for liver enzyme and tissue analyses. The COX-2 transgenic mice showed significantly higher serum ALT and AST levels than wild-type mice (Fig. 3). Histological examination of the liver tissues revealed more prominent hemorrhage necrosis, hepatocyte apoptosis, and degeneration in COX-2 transgenic mice compared with wild-type mice (Fig. 4).

**FIGURE 4.** Hepatic expression of COX-2 enhances LPS-induced liver injury. The COX-2 transgenic mice and the age- and sex-matched wild-type mice were administered i.p. 30 ng/g body weight of LPS in combination with 800 \(\mu\)g/g body weight of \(\alpha\)-GalN. The animals were sacrificed 4 h after injection and the liver tissues were harvested for histological evaluation. Formalin-fixed and paraffin-embedded sections (5 \(\mu\)m thick) were stained with H&E, TUNEL, and caspase-3. Histopathological characteristics of the liver tissues are shown. H&E stain (upper) at a magnification of \(\times 200\). The livers of COX-2 transgenic (COX-2 Tg) mice (right) exhibit more prominent hemorrhage necrosis, hepatocyte apoptosis, and degeneration when compared with the livers of wild-type mice (left). TUNEL stain (middle) at a magnification of \(\times 200\) in liver tissues of LPS-treated mice. The number of TUNEL-positive hepatocytes in COX-2 transgenic mice is significantly higher than the number in wild-type mice. Caspase-3 immunostain (lower) at a magnification of \(\times 200\) in liver tissue. COX-2 transgenic mice show a significantly higher number of caspase-3-positive apoptotic hepatocytes than wild-type mice.

**FIGURE 5.** Liver tissue analysis for PARP, caspase-3, and caspase-9. The COX-2 transgenic (COX-2 Tg) mice, EP1 knockout mice, and matched wild-type mice were subjected to LPS and \(\alpha\)-GalN injection (i.p.). The animals were sacrificed 4 h after injection. The liver tissues were obtained and the cellular proteins were subjected to SDS-PAGE and Western blot analysis to determine the levels of PARP, caspase-3, and caspase-9 as described in Materials and Methods. LPS/\(\alpha\)-GalN treatment for 4 h induced much higher cleavage of PARP, caspase-3, and caspase-9 in COX-2 transgenic mice than induced in wild-type or EP1 knockout mice.
prominent liver damage in the COX-2 transgenic than in wild-type mice (Fig. 4). In the COX-2 transgenic group, massive hemorrhagic necrosis and hepatocyte apoptosis were observed, with prominent vascular congestion and neutrophil infiltration; only residual areas of surviving hepatocytes were present, showing vacuolar degeneration and cytoplasmic swelling. In contrast, only mild scattered necrosis and apoptosis were observed in the wild-type mice. The number of TUNEL-positive hepatocytes in the liver tissue sections. As shown in Fig. 4, the number of TUNEL-positive hepatocytes show significant cellular swelling, we further performed immunohistochemical stain for caspase-3 in liver tissue sections. As shown in Fig. 4, the number of TUNEL-positive hepatocytes shows significant cellular swelling, we further performed immunohistochemical stain for caspase-3.

**FIGURE 6.** Increased expression of JNK-2 in COX-2 transgenic mice. The liver tissues from the COX-2 transgenic mice and their matched wild-type mice were homogenized. The cellular proteins were subjected to SDS-PAGE and Western blot analysis to determine the protein level of JNK-2. Western blot for β-actin was used as the loading control. Higher level of JNK-2 was observed in the liver tissues from the COX-2 transgenic (COX-2 Tg) mice when compared with the wild-type mice. The bottom panel represents the ratio between JNK-2 and β-actin by densitometry analysis. *, p < 0.01.

**FIGURE 7.** Increased phosphorylation of JNK in COX-2 transgenic mice treated with LPS/GalN injection. The COX-2 transgenic (COX-2 Tg) mice and matched wild-type mice were sacrificed 4 h after LPS/D-GalN injection. The liver tissues were homogenized and the extracted proteins were subjected to SDS-PAGE and Western blot analysis using the Ab against phospho-JNK (Cell Signaling Technology). Western blot for β-actin was used as the loading control. The bottom panel represents the ratio between phosphorylated p54-JNK-2 and β-actin by densitometry analysis. *, p < 0.01 compared with wild-type mice treated LPS/D-GalN or COX-2 transgenic mice treated with saline.

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Vehicle, pg/mg</th>
<th>LPS/GalN Treatment, pg/mg</th>
<th>Wild Type</th>
<th>COX-2 Transgenic</th>
<th>Wild Type</th>
<th>COX-2 Transgenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGF</td>
<td>21.81 ± 5.62</td>
<td>18.13 ± 3.22</td>
<td>20.91 ± 1.98</td>
<td>25.68 ± 5.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-γ</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-12 (p40/p70)</td>
<td>0.29 ± 0.02</td>
<td>0.61 ± 0.10</td>
<td>1.59 ± 0.51*</td>
<td>0.68 ± 0.05</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>TNF-α</td>
<td>ND</td>
<td>ND</td>
<td>0.20 ± 0.05**</td>
<td>0.25 ± 0.15</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>VEGF</td>
<td>2.43 ± 0.22</td>
<td>2.60 ± 0.70</td>
<td>1.12 ± 0.14</td>
<td>1.00 ± 0.06</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-2</td>
<td>0.88 ± 0.11</td>
<td>1.00 ± 0.15</td>
<td>1.21 ± 0.20</td>
<td>0.84 ± 0.09</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-4</td>
<td>ND</td>
<td>ND</td>
<td>0.99 ± 0.08</td>
<td>1.05 ± 0.46</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-5</td>
<td>3.78 ± 1.25</td>
<td>3.50 ± 0.43</td>
<td>9.48 ± 2.04*</td>
<td>3.81 ± 0.35</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IP-10</td>
<td>2.68 ± 0.40</td>
<td>3.89 ± 1.09</td>
<td>386.00 ± 129.13**</td>
<td>139.27 ± 6.96</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>KC</td>
<td>1.12 ± 0.12</td>
<td>1.38 ± 0.14</td>
<td>3.57 ± 0.42**</td>
<td>1.41 ± 0.02</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.19 ± 0.02</td>
<td>0.21 ± 0.02</td>
<td>2.77 ± 0.50**</td>
<td>1.22 ± 0.13</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>MIG</td>
<td>0.32 ± 0.04</td>
<td>0.39 ± 0.07</td>
<td>4.44 ± 0.12**</td>
<td>5.45 ± 1.24</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>0.35 ± 0.05</td>
<td>0.52 ± 0.10</td>
<td>8.96 ± 0.93**</td>
<td>4.04 ± 0.06</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0.50 ± 0.07</td>
<td>0.60 ± 0.10</td>
<td>6.71 ± 0.99**</td>
<td>4.07 ± 1.28</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-6</td>
<td>3.13 ± 0.43</td>
<td>3.50 ± 0.54</td>
<td>3.10 ± 0.57</td>
<td>2.35 ± 0.49</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>ND</td>
<td>ND</td>
<td>51.27 ± 14.81**</td>
<td>12.22 ± 0.08</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-1α</td>
<td>0.47 ± 0.13</td>
<td>0.52 ± 0.10</td>
<td>1.30 ± 0.49</td>
<td>1.54 ± 0.34</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-13</td>
<td>1.32 ± 0.19</td>
<td>1.70 ± 0.31</td>
<td>0.48 ± 0.16</td>
<td>0.29 ± 0.08</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-17</td>
<td>0.30 ± 0.05</td>
<td>0.41 ± 0.11</td>
<td>0.15 ± 0.04</td>
<td>0.48 ± 0.29</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

*Data represent wet weight of liver tissue and are expressed as mean ± SD from three to five experiments. *p < 0.05 and **p < 0.01 compared with wild-type animals treated with vehicle alone. ND, Not detectable (below detectable limit of the assay). FGF, fibroblast growth factor; IP-10, IFN-inducible protein-10; MIG, monokine-induced by IFN-γ; VEGF, vascular endothelial growth factor.
caspase-3-positive cells in the COX-2 transgenic mice is also significantly higher than in wild-type mice (33.18 ± 0.39% vs 8.80 ± 0.02%, p < 0.01). The caspase-3-positive counts are slightly lower than TUNEL-positive counts, suggesting that some of the TUNEL-positive cells might reflect necrotic hepatocytes. The liver tissues from the COX-2 transgenic mice and wild-type mice treated with LPS/D-GalN for 4 hours were then analyzed by Western blot analysis to determine the levels of PARP, caspase-3, and caspase-9. As shown in Fig. 5, LPS/D-GalN treatment for 4 h induced much more prominent cleavage of PARP, caspase-3, and caspase-9 in COX-2 transgenic mice than in wild-type mice. The presence of weak caspase-3 and PARP cleavage in wild-type mice at this time point indicates the occurring of hepatocyte apoptosis in these control animals, which is consistent with the documented caspase activation in LPS/D-GalN-induced liver injury (25–30). The relatively weak intensity of the cleaved caspase-3 and PARP in our study may be due to several factors, including the early time point in our study, the different concentrations of LPS/D-GalN, the different Ab sources or titers, or the different methods for apoptotic detection. Collectively, our findings from the histopathological evaluation, TUNEL assay, caspase-3 immunocytochemical stain, and immunoblotting all indicate the presence of increased hepatocyte apoptosis in COX-2 transgenic mice, despite that some of the injured hepatocytes may represent hepatocyte necrosis or apoptosis. Thus, although hepatic overexpression of COX-2 did not cause liver inflammation or hepatocyte injury under baseline conditions, it enhanced LPS-induced hepatocyte apoptosis/necrosis, tissue damage and liver failure. These observations suggest a potential role of hepatocyte COX-2 in the pathogenesis of LPS-induced liver injury.

Given the documented role of inflammatory cytokines in LPS/D-GalN-induced liver injury (31, 32), we examined the expression of key inflammatory cytokines in liver tissues by using the Luminex cytokine bead immunoassays. As shown in Table II, although LPS/D-GalN treatment significantly increased the production of a repertoire of inflammatory cytokines including IL-1α, IL-1β, TNF-α,
IP-10, MIP-1α, IL-10, IL-12, MCP-1, KC, and MIG in the wild-type mice, the cytokine profiles were not significantly different between the COX-2 transgenic and wild-type groups. These findings suggest that COX-2-mediated enhancement of liver injury most likely involves mechanism independent of cytokine production.

JNK is a member of the MAPK family that is known to trigger apoptosis in response to environmental stresses as well as inflammatory cytokines (33). The JNK signaling pathway is activated in various forms of liver injury (34–38). Recently, several studies, based on the gene knockout approach, have convincingly demonstrated the critical role of JNK in hepatocyte apoptosis, which was induced by Con A, methionine- and choline-deficient diet, or LPS/α-GalN (36–39). Because JNK-2 plays an essential role in LPS/α-GalN-induced liver injury through direct activation of caspase (37), we examined whether overexpression of COX-2 in hepatocytes might activate JNK-2 in our system. Indeed, the COX-2 transgenic mice express significantly higher level of JNK-2 in the liver when compared with the wild-type mice (Fig. 6). Higher phosphorylation of p54-JNK is also observed in the COX-2 transgenic livers when compared with the wild-type controls after LPS/α-GalN injection (Fig. 7). Therefore, up-regulation of JNK-2 may represent an important mechanism for COX-2-mediated exacerbation of liver injury. Nonetheless, in light of the complexity of LPS/α-GalN-induced liver injury, the possibility of other mechanisms cannot be excluded.

The effect of COX-2 is mediated by prostanoids that bind their G protein-coupled receptors. The most abundant prostanoid in the liver is PGE2, which exerts actions through binding its membrane EP receptors (6–8). Although all four different EP receptor subtypes (EP1–4) are expressed in hepatic cells, studies have suggested a potential role of EP1 receptor in primary and transformed hepatocytes (40, 41). To determine whether EP1 receptor mediates COX-2 effect in LPS-induced liver injury, we used both pharmacological and genetic approaches to inhibit EP1 function and expression. Pretreatment of COX-2 transgenic mice with the specific EP1 receptor antagonist ONO-8711 for 45 min prevented LPS/α-GalN-induced transaminase increase as well as hepatocyte damage (Fig. 8). The protective effect by ONO-8711 appears similar to that
by NS-398, a selective COX-2 inhibitor (Fig. 8). Accordingly, mice with genetic ablation of EP₁ (n = 15) showed prolonged survival compared with wild-type mice after LPS/ω-GalN injection (Table I). The LPS-induced hepatocyte apoptosis and liver damage in EP₁ knockout mice was notably less than in the wild-type mice. Four hours after LPS/ω-GalN injection, the TUNEL-positive hepatocytes in EP₁ knockout mice (3.42 ± 0.02%) was significantly lower than hepatocytes in wild-type mice (11.77 ± 0.04%, p < 0.01) (Fig. 9). Similarly, the number of caspase-3-positive cells in the EP₁ knockout mice (2.12 ± 0.01%) was also significantly lower than in wild-type mice (8.80 ± 0.02%, p < 0.01). These findings indicate that EP₁ receptor may play a role in LPS-induced liver injury. It appears that JNK-2 may be involved in EP₁ effect, given the decreased level of JNK-2 in the liver tissues from LPS/ω-GalN treated EP₁ mice (Fig. 10).

Discussion

LPS/ω-GalN-induced liver injury is a well-established model of acute liver failure in mice. In this model ω-GalN blocks gene transcription in the liver and LPS in turn induces an acute cytokine-dependent liver inflammation accompanied by massive liver apoptosis and death of the animals (11, 17, 18, 42, 43). LPS activates Kupffer cells, resulting in overproduction of large amounts of cytokines, which subsequently trigger liver inflammation and tissue damage (31, 32). In addition to cytokines, prostaglandins have also been suggested to participate in LPS-induced liver injury (44). The synthesis of prostaglandins is tightly controlled by COXs (including COX-1 and COX-2), which catalyze the conversion of arachidonic acid to prostaglandins. Whereas COX-1 is constitutively expressed in most tissues, COX-2 is inducible by a variety of factors including cytokines and endotoxin. Indeed, the expression of COX-2 protein is induced in LPS-treated liver from rats (44). These results indicate that COX-2 may contribute to liver injury. However, much remains unknown about the involvement of hepatic COX-2 in liver injury during endotoxemia. In this study, we provide novel evidence for an important role of COX-2 in hepatocytes for LPS-induced liver injury. Our data indicate that COX-2 transgenic mice develop accelerated liver injury in response to LPS/ω-GalN treatment. Additionally, we have shown that the LPS/ω-GalN-induced liver damage in the COX-2 transgenic mice is alleviated by pharmacologic inhibition of COX-2 and EP₁. Furthermore, the EP₁ knockout mice exhibit less LPS/ω-GalN-induced liver damage and less hepatocyte apoptosis with prolonged survival when compared with the wild-type mice. These results demonstrate an important role of COX-2/EP₁ signaling cascade in LPS-induced hepatic injury.

It is worth mentioning that in our transgenic mice model the expression of COX-2 is driven by the albumin promoter and is exclusively present in hepatocytes. Therefore, the accelerated liver injury observed in the COX-2 transgenic mice indicates the contribution of COX-2 in hepatocytes to LPS-induced liver injury. Additionally, it is of note that COX-2 induction occurs predominantly in Kupffer cells in response to LPS and the effects of PGE₂ on hepatocytes are paracrine, whereas in our COX-2 transgenic model the effects are autocrine. Although adult hepatocytes do not express COX-2 under normal conditions, the level of COX-2 in hepatocytes is increased during chronic inflammatory liver diseases (45–48). Therefore, our findings in this study suggest that elevated hepatic COX-2 during chronic inflammatory liver diseases may represent a predisposing risk factor for LPS-induced liver failure.

The liver tissues from the COX-2 transgenic and wild-type mice showed a similar cytokine expression profile under baseline conditions (without LPS/ω-GalN treatment). These findings, along with histological evaluation of the liver tissues, suggest that overexpression of COX-2 alone in hepatocytes does not significantly alter hepatic cytokine production or inflammatory response. We observed that LPS/ω-GalN treatment of wild-type mice significantly increased the production of several key inflammatory cytokines (including IL-1α, IL-1β, TNF-α, IP-10, MIP-1α, IL-10, IL-12, MCP-1, KC, and MIG); these data are consistent with the documented role of inflammatory cytokines in LPS-induced liver inflammation and tissue damage. It is of note that transgenic overexpression of COX-2 in hepatocytes did not further enhance cytokine production after LPS/ω-GalN treatment, suggesting that COX-2-mediated enhancement of liver injury is likely mediated by mechanism independent of cytokine production. In this context, it is noteworthy that our data point toward the involvement of JNK-2 in this process.

Prostanoids exert their biological actions primarily via their respective G protein-coupled receptor superfamily of seven-transmembrane spanning proteins on the cell surface membrane (7, 8). PGE₂ can potentially interact with four types of receptors (EP₁, EP₂, EP₃, and EP₄). The EP₁ receptor is coupled with Gₛ protein and thus signals through phospholipase C and intracellular Ca²⁺; the EP₂ and EP₃ receptors are coupled with Gₛ protein, signaling through elevation of intracellular cAMP level and activation of protein kinase A; the EP₄ receptor is coupled with Gₛ protein and signals through reduction of intracellular cAMP. In this study, we show that the LPS/ω-GalN-induced liver injury is blocked by the EP₁ receptor antagonist, ONO-8711. Furthermore, the EP₁ knockout mice show reduced liver injury after LPS/ω-GalN challenge. These findings suggest the involvement of EP₁ receptor in LPS/ω-GalN-induced liver injury.

Our results in this study suggest that inhibition of COX-2-EP₁ signaling pathway may reduce LPS-induced liver injury. Because COX-2 inhibitors are associated with cardiovascular side effect, which is believed to be largely due to inhibition of the antithrombotic prostacyclin (49–51), blocking EP₁ receptor is expected to effectively prevent LPS-related liver injury without inhibiting prostacyclin and thus incurring no significant side effects. Therefore, inhibiting EP₁ may represent a potentially effective and safe approach for amelioration of LPS-induced liver damage. The availability of transgenic mice with hepatic expression of COX-2 will allow future studies to determine the role of COX-2-controlled
prostaglandin signaling in the pathogenesis of various inflammatory and neoplastic liver diseases.

Acknowledgments

We thank Dr. Beverly Koller at the University of North Carolina and Dr. John McNeish at Pfizer for providing the EP1 knockout mice. The EP1 receptor antagonist ONO-5711 was provided by the Ono Pharmaceutical Company, Ltd. (Osaka, Japan).

Disclosures

The authors have no financial conflict of interest.

References